SPARC accelerates disease progression in experimental crescentic glomerulonephritis

American Journal of Pathology

Volumn 174, Issue 5, 2009, Pages 1827-1836

  Sussman, Amy N ^a   Sun, Tong ^a   Krofft, Ronald M ^a   Durvasula, Raghu V ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; OSTEONECTIN; MEMBRANE PROTEIN; NEPHRIN; PODOCIN; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; CONTROLLED STUDY; CRESCENTIC GLOMERULONEPHRITIS; EXPERIMENTAL MODEL; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN SECRETION; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; DISEASE COURSE; DISEASE MODEL; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GLOMERULONEPHRITIS; IMMUNOBLOTTING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; OSTEONECTIN; PODOCYTES;

EID: 65649088692     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080464     Document Type: Article

References (49)

1. Lane TF, Sage EH: The biology of SPARC, a protein that modulates cell- matrix interactions. FASEB J 1994, 8:163-173 (Pubitemid 24067139)
2. Brekken RA, Sage EH: SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol 2000, 19:569-580
3. Murphy-Ullrich JE: The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J Clin Invest 2001, 107:785-790
4. Francki A, Sage EH: SPARC and the kidney glomerulus: matricellular proteins exhibit diverse functions under normal and pathological conditions. Trends Cardiovasc Med 2001, 11:32-37 (Pubitemid 32549730)
5. Durvasula RV, Shankland SJ: Mechanical strain increases SPARC levels in podocytes: implications for glomerulosclerosis. Am J Physiol Renal Physiol 2005, 289:F577-F584 (Pubitemid 41208473)
6. Kanauchi M, Nishioka M, Dohi K: Secreted protein acidic and rich in cysteine (SPARC) in patients with diabetic nephropathy and tubulointerstitial injury. Diabetologia 2000, 43:1076-1077 (Pubitemid 30655730)
7. Taneda S, Pippin JW, Sage EH, Hudkins KL, Takeuchi Y, Couser WG, Alpers CE: Amelioration of diabetic nephropathy in SPARC-null mice. J Am Soc Nephrol 2003, 14:968-980 (Pubitemid 36359278)
8. Gruber HE, Sage EH, Norton HJ, Funk S, Ingram J, Hanley EN, Jr.: Targeted deletion of the SPARC gene accelerates disc degeneration in the aging mouse. J Histochem Cytochem 2005, 53:1131-1138
9. Norose K, Lo WK, Clark JI, Sage EH, Howe CC: Lenses of SPARC-null mice exhibit an abnormal cell surface-basement membrane interface. Exp Eye Res 2000, 71:295-307
10. Norose K, Clark JI, Syed NA, Basu A, Heber-Katz E, Sage EH, Howe CC: SPARC deficiency leads to early-onset cataractogenesis. Invest Ophthalmol Vis Sci 1998, 39:2674-2680 (Pubitemid 28558226)
11. Ophascharoensuk V, Pippin JW, Gordon KL, Shankland SJ, Couser WG, Johnson RJ: Role of intrinsic renal cells versus infiltrating cells in glomerular crescent formation. Kidney Int 1998, 54:416-425 (Pubitemid 28357404)
12. Shankland SJ, Pippin J, Pichler RH, Gordon KL, Friedman S, Gold LI, Johnson RJ, Couser WG: Differential expression of transforming growth factor-beta isoforms and receptors in experimental membranous nephropathy. Kidney Int 1996, 50:116-124 (Pubitemid 26323705)
13. Ophascharoensuk V, Fero ML, Hughes J, Roberts JM, Shankland SJ: The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury. Nat Med 1998, 4:575-580 (Pubitemid 28237356)
14. Sage H, Vernon RB, Decker J, Funk S, Iruela-Arispe ML: Distribution of the calcium-binding protein SPARC in tissues of embryonic and adult mice. J Histochem Cytochem 1989, 37:819-829 (Pubitemid 19156464)
15. Alpers CE, Hudkins KL, Pritzl P, Johnson RJ: Mechanisms of clearance of immune complexes from peritubular capillaries in the rat. Am J Pathol 1991, 139:855-867
16. Jat PS, Noble MD, Ataliotis P, Tanaka Y, Yannoutsos N, Larsen L, Kioussis D: Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse. Proc Natl Acad Sci USA 1991: 88:5096-5100 (Pubitemid 21914690)
17. Mundel P, Reiser J, Zuniga Mejia Borja A, Pavenstadt H, Davidson GR, Kriz W, Zeller R: Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997, 236:248-258 (Pubitemid 27452369)
18. Griffin S, Olivier PJ, Pippin JW, Roberts, JM, Shankland, SJ: Cyclin I protects podocytes from apoptosis. J Biol Chem 2006, 38:28048-28057 (Pubitemid 44414518)
19. Wada T, Pippin JW, Terada Y, Shankland SJ: The cyclin-dependent kinase inhibitor p21 is required for TGF-beta1-induced podocyte apoptosis. Kidney Int 2005, 68:1618-1629 (Pubitemid 43169907)
20. Mundel P, Reiser J, Kriz W: Induction of differentiation in cultured rat and human podocytes. J Am Soc Nephrol 1997, 8:697-705 (Pubitemid 27493583)
21. Shankland SJ, Pippin JW, Reiser J, Mundel P: Podocytes in culture: past, present, and future. Kidney Int 2007, 72:26-36 (Pubitemid 47014453)
22. Petermann AT, Hiromura K, Blonski M, Pippin J, Monkawa T, Durvasula R, Couser WG, Shankland SJ: Mechanical stress reduces podocyte proliferation in vitro. Kidney Int 2002, 61:40-50 (Pubitemid 34075129)
23. Logar CM, Brinkkoetter PT, Krofft RD, Pippin JW, Shankland SJ: Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int 2007, 72:489-498 (Pubitemid 47237613)
24. Dandapani SV, Sugimoto H, Matthews BD, Kolb RJ, Sinha S, Gerszten RE, Zhou J, Ingber DE, Kalluri R, Pollak MR: Alpha-actinin-4 is required for normal podocyte adhesion. J Biol Chem 2007, 282:467-477 (Pubitemid 47076665)
25. Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J: Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 2005, 16:1733-1741 (Pubitemid 41716479)
26. Kriz W, Elger M, Nagata M, Kretzler M, Uiker S, Koeppen-Hageman I, Tenschert S, Lemley KV: The role of podocytes in the development of glomerular sclerosis. Kidney Int Suppl 1994, 45:S64-S72 (Pubitemid 24043598)
27. Lemley KV: A basis for accelerated progression of diabetic nephropathy in Pima Indians. Kidney Int Suppl 2003, S38-S42
28. Lemley KV, Lafayette RA, Safai M, Derby G, Blouch K, Squarer A, Myers BD: Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002, 61:1475-1485 (Pubitemid 34304509)
29. Shankland SJ: The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006, 69:2131-2147 (Pubitemid 43882099)
30. Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Holzman LB, Wiggins RC: Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005, 16:2941-2952
31. Hara M, Yanagihara T, Kihara I: Urinary podocytes in primary focal segmental glomerulosclerosis. Nephron 2001, 89:342-347 (Pubitemid 34701770)
32. Petermann A, Floege J: Podocyte damage resulting in podocyturia: a potential diagnostic marker to assess glomerular disease activity. Nephron Clin Pract 2007, 106:c61-66 (Pubitemid 46933393)
33. Petermann AT, Krofft R, Blonski M, Hiromura K, Vaughn M, Pichler R, Griffin S, Wada T, Pippin J, Durvasula R, Shankland SJ: Podocytes that detach in experimental membranous nephropathy are viable. Kidney Int 2003, 64:1222-1231 (Pubitemid 37153787)
34. Petermann AT, Pippin J, Krofft R, Blonski M, Griffin S, Durvasula R, Shankland SJ: Viable podocytes detach in experimental diabetic nephropathy: potential mechanism underlying glomerulosclerosis. Nephron Exp Nephrol 2004, 98:e114-e123 (Pubitemid 40069645)
35. Vogelmann SU, Nelson WJ, Myers BD, Lemley KV: Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 2003, 285:F40-F48 (Pubitemid 36818460)
36. Patari A, Forsblom C, Havana M, Taipale H, Groop PH, Holthofer H: Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes 2003, 52:2969-2974 (Pubitemid 37466867)
37. Francki A, Motamed K, McClure TD, Kaya M, Murri C, Blake DJ, Carbon JG, Sage EH: SPARC regulates cell cycle progression in mesangial cells via its inhibition of IGF-dependent signaling. J Cell Biochem 2003, 88:802-811 (Pubitemid 36258830)
38. Pichler RH, Bassuk JA, Hugo C, Reed MJ, Eng E, Gordon KL, Pippin J, Alpers CE, Couser WG, Sage EH, Johnson RJ: SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro. Am J Pathol 1996, 148:1153-1167 (Pubitemid 26108253)
39. Ka SM, Rifai A, Chen JH, Cheng CW, Shui HA, Lee HS, Lin YF, Hsu LF, Chen A: Glomerular crescent-related biomarkers in a murine model of chronic graft versus host disease. Nephrol Dial Transplant 2006, 21:288-298 (Pubitemid 43159981)
40. Pichler RH, Hugo C, Shankland SJ, Reed MJ, Bassuk JA, Andoh TF, Lombardi DM, Schwartz SM, Bennett WM, Alpers CE, Sage EH, Johnson RJ, Couser WG: SPARC is expressed in renal interstitial fibrosis and in renal vascular injury. Kidney Int 1996, 50:1978-1989
41. Socha MJ, Manhiani M, Said N, Imig JD, Motamed K: Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension. Am J Pathol 2007, 171:1104-1112 (Pubitemid 47582886)
42. Hara M, Yanagihara T, Kihara I: Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schonlein-Henoch purpura nephritis. Clin J Am Soc Nephrol 2007, 2:231-238
43. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, Ebihara I, Koide H: Urinary podocytes for the assessment of disease activity in lupus nephritis. Am J Med Sci 2000, 320:112-116 (Pubitemid 30664184)
44. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, Koide H: Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000, 15:1379-1383
45. Shi Q, Bao S, Song L, Wu Q, Bigner DD, Hjelmeland AB, Rich JN: Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene 2007, 26:4084-4094 (Pubitemid 46920166)
46. Weaver MS, Workman G, Sage EH: The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase. J Biol Chem 2008, 283:22826-22837
47. Greenwood JA, Murphy-Ullrich JE: Signaling of de-adhesion in cellular regulation and motility. Microsc Res Tech 1998, 43:420-432 (Pubitemid 28565789)
48. Sage EH, Bornstein P: Extracellular proteins that modulate cell-matrix interactions, SPARC, tenascin, and thrombospondin. J Biol Chem 1991, 266:14831-14834 (Pubitemid 21907577)
49. Weaver MS, Sage EH, Yan Q: Absence of SPARC in lens epithelial cells results in altered adhesion and extracellular matrix production in vitro. J Cell Biochem 2006, 97:423-432 (Pubitemid 43167155)